Results 231 to 240 of about 88,625 (333)

Nanodroplet Array Platform for Integrated Synthesis and Screening of MEK Inhibitors: a Miniaturized Approach to Early Drug Discovery

open access: yesAngewandte Chemie International Edition, EarlyView.
We present a nanodroplet array platform that integrates solid‐phase synthesis, MALDI‐MS analysis, and cell‐based screening. Using nanoliter droplets, we synthesized and tested 325 potential MEK inhibitors and identified 46 active compounds. This miniaturized approach combines chemistry and biology on a single chip, reducing time, cost, and material use
Maximilian Seifermann   +10 more
wiley   +1 more source

Raw Material Economisation in Aotearoa New Zealand: Evidence for Manufacture and Recycling of Adzes on Ahuahu Great Mercury Island

open access: yesArchaeology in Oceania, EarlyView.
ABSTRACT Raw materials are used to characterise the early settlement of Aotearoa Te Wai Pounamu New Zealand by Māori. Current models suggest change in raw material use over time occurred in response to changing social organisation and reduced resource availability. However, few studies have examined spatial variation in raw material use.
Rebecca Phillipps   +3 more
wiley   +1 more source

Identifying Predictive Biomarkers of Response in Patients With Rheumatoid Arthritis Treated With Adalimumab Using Machine Learning Analysis of Whole‐Blood Transcriptomics Data

open access: yesArthritis &Rheumatology, EarlyView.
Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to nonresponse or adverse effects.
Chuan Fu Yap   +12 more
wiley   +1 more source

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

open access: yesArthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Prognostic value of lupus anticoagulant and anti‐β2 glycoprotein I antibody in adverse pregnancy outcomes.

open access: yesArthritis &Rheumatology, Accepted Article.
Objective International criteria for antiphospholipid syndrome (APS) include lupus anticoagulant (LA), anticardiolipin (aCL) immunoglobulin (Ig) G and IgM, and anti‐β2‐glycoprotein I (β2GPI) IgG and IgM. However, evidence supporting their prognostic value or treatment efficacy in improving live birth rates is limited.
Megumi Nonobe   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy